◎ Sugi Atlas

Atlas / Gene / FABP6

FABP6

gene
On this page

Also known as I-15PILLBPI-BAPILBP3I-BABPILBPI-BALB

Summary

FABP6 (fatty acid binding protein 6, HGNC:3561) is a protein-coding gene on chromosome 5q33.3, encoding Gastrotropin (P51161). Binds to bile acids and is involved in enterohepatic bile acid metabolism.

This gene encodes the ileal fatty acid binding protein. Fatty acid binding proteins are a family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids and other hydrophobic ligands. FABP6 and FABP1 (the liver fatty acid binding protein) are also able to bind bile acids. It is thought that FABPs roles include fatty acid uptake, transport, and metabolism. Transcript variants generated by alternate transcription promoters and/or alternate splicing have been found for this gene.

Source: NCBI Gene 2172 — RefSeq curated summary.

At a glance

  • GWAS associations: 7
  • Clinical variants (ClinVar): 32 total
  • Druggable target: yes — 1 molecules with ChEMBL bioactivity
  • MANE Select transcript: NM_001445

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:3561
Approved symbolFABP6
Namefatty acid binding protein 6
Location5q33.3
Locus typegene with protein product
StatusApproved
AliasesI-15P, ILLBP, I-BAP, ILBP3, I-BABP, ILBP, I-BALB
Ensembl geneENSG00000170231
Ensembl biotypeprotein_coding
OMIM600422
Entrez2172

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 15 protein_coding, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000393980, ENST00000402432, ENST00000521362, ENST00000523955, ENST00000877317, ENST00000877318, ENST00000877319, ENST00000877320, ENST00000915607, ENST00000915608, ENST00000915609, ENST00000968081, ENST00000968082, ENST00000968083, ENST00000968084, ENST00000968085, ENST00000968086

RefSeq mRNA: 3 — MANE Select: NM_001445 NM_001040442, NM_001130958, NM_001445

CCDS: CCDS43393, CCDS4349

Canonical transcript exons

ENST00000402432 — 4 exons

ExonStartEnd
ENSE00001549567160229506160229624
ENSE00003488680160232098160232273
ENSE00003528891160238606160238716
ENSE00003585046160234820160234909

Expression profiles

Bgee: expression breadth ubiquitous, 196 present calls, max score 99.96.

FANTOM5 (CAGE): breadth broad, TPM avg 2.5887 / max 1010.3678, expressed in 384 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter IDTPM avgSamples expressed
598871.7586315
598880.649223
598900.106926
598860.039719
598890.034318

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
ileal mucosaUBERON:000033199.96gold quality
right uterine tubeUBERON:000130298.70gold quality
bronchial epithelial cellCL:000232898.06gold quality
epithelium of bronchusUBERON:000203197.24gold quality
small intestine Peyer’s patchUBERON:000345496.48gold quality
bronchusUBERON:000218595.55gold quality
olfactory segment of nasal mucosaUBERON:000538693.12gold quality
nucleus accumbensUBERON:000188290.88gold quality
caudate nucleusUBERON:000187389.67gold quality
small intestineUBERON:000210889.45gold quality
putamenUBERON:000187489.18gold quality
male germ line stem cell (sensu Vertebrata) in testisCL:0000089 ∩ UBERON:000047388.78gold quality
hypothalamusUBERON:000189888.60gold quality
substantia nigraUBERON:000203887.21gold quality
primordial germ cell in gonadCL:0000670 ∩ UBERON:000099187.10gold quality
mucosa of paranasal sinusUBERON:000503086.62gold quality
cingulate cortexUBERON:000302786.24gold quality
anterior cingulate cortexUBERON:000983586.17gold quality
medial globus pallidusUBERON:000247785.14gold quality
midbrainUBERON:000189184.89gold quality
prefrontal cortexUBERON:000045184.76gold quality
amygdalaUBERON:000187684.19gold quality
right adrenal gland cortexUBERON:003582783.42gold quality
right adrenal glandUBERON:000123382.75gold quality
left adrenal gland cortexUBERON:003582582.57gold quality
dorsolateral prefrontal cortexUBERON:000983482.16gold quality
globus pallidusUBERON:000187582.03gold quality
Brodmann (1909) area 9UBERON:001354082.01gold quality
right frontal lobeUBERON:000281081.95gold quality
left adrenal glandUBERON:000123481.75gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

ExperimentMarker?Max mean expression
E-CURD-46yes78717.10
E-GEOD-125970yes52821.86
E-ANND-3no0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): JUN, NR0B2, NR1H3, NR1H4, PPARA, PPARD, SP1, SREBF1, SREBF2, SSRP1, TBP, TCF3

Literature-anchored findings (GeneRIF, showing 18)

  • NMR structure of human ileal lipid-binding protein-cholyltaurine complex and its comparison with homologous structures (PMID:12486725)
  • In keeping with its role in the enterohepatic circulation and ileal reabsorption of bile acids, the gene promoter contains consensus elements for CDX2 and FXR. More than one transcription start site has been identified. (PMID:14654244)
  • the I-BABP gene may be a novel target for PPAR in humans (PMID:15936983)
  • ASBT and ILBP protein were 48% and 67% lower in normal weight gallstone carriers than in controls (P < 0.05); similar differences were found for mRNA expression levels. (PMID:16237211)
  • The expression of FABP6 was higher in primary colorectal cancers and adenomas than in normal epithelium, but was dramatically decreased in lymph node metastases, suggesting that FABP6 may play an important role in early carcinogenesis. (PMID:16951225)
  • The-putative functional-Thr79Met substitution of FABP6 confers a protective effect on type 2 diabetes in obese individuals. (PMID:19744871)
  • Ursodeoxycholic acid induces unique conformational changes in IBABP. (PMID:22223860)
  • NMR data are in agreement with a conformational selection model we proposed earlier for I-BABP and support the hypothesis of an allosteric mechanism of ligand binding (PMID:22329738)
  • show, using electrospray ionization mass spectroscopy, that human ILBP binds bile acids with a 3:1 ratio, even at low protein and ligand concentrations (PMID:23758264)
  • Analysis of slow and fast motions in I-BABP indicates largely different energy landscapes for the apo and holo states suggesting that optimization of binding interactions might be achieved by altering the dynamic behavior of specific protein segments. (PMID:25073073)
  • Structural determinants of ligand binding in the ternary complex of human ileal bile acid binding protein with glycocholate and glycochenodeoxycholate obtained from solution NMR (PMID:26613247)
  • Experimental analysis showed the importance of LEF1, ETV4 and FABP6 as three co-regulated prognostic markers in patients with colorectal cancer metastasis. (PMID:30193961)
  • Functional suppression of FABP7 significantly inhibited SKRC10 clear cell renal cell carcinoma (ccRCC) cells growth and resulted in a significant reduction of the invasive potential but did not cause growth inhibition of SKRC7 cells. Functional suppression of FABP6 resulted in significant growth inhibition of SKRC7 cells. This is the first report about the complementary role of FABP6 for FABP7 in ccRCC. (PMID:30442117)
  • Study of FABP’s interactome and detecting new molecular targets in clear cell renal cell carcinoma. (PMID:31602654)
  • Inhibition of FABP6 Reduces Tumor Cell Invasion and Angiogenesis through the Decrease in MMP-2 and VEGF in Human Glioblastoma Cells. (PMID:34685761)
  • Fatty Acid Binding Protein 6 Inhibition Decreases Cell Cycle Progression, Migration and Autophagy in Bladder Cancers. (PMID:35216267)
  • Multiple Timescale Dynamic Analysis of Functionally-Impairing Mutations in Human Ileal Bile Acid-Binding Protein. (PMID:36232642)
  • REST Promotes Autophagy in Gastric Cancer by Transcriptionally Activating FABP6 to Inhibit the Akt/mTOR Signaling Pathway. (PMID:38940038)

Cross-species orthologs

5 orthologs

OrganismSymbolGene ID
danio_reriofabp6ENSDARG00000044566
mus_musculusFabp6ENSMUSG00000020405
rattus_norvegicusFabp6ENSRNOG00000003902
caenorhabditis_elegansWBGENE00002259
caenorhabditis_elegansWBGENE00002260

Paralogs (15): RBP2 (ENSG00000114113), RBP1 (ENSG00000114115), FABP3 (ENSG00000121769), RBP5 (ENSG00000139194), CRABP2 (ENSG00000143320), FABP2 (ENSG00000145384), PMP2 (ENSG00000147588), RBP7 (ENSG00000162444), FABP1 (ENSG00000163586), FABP7 (ENSG00000164434), FABP5 (ENSG00000164687), CRABP1 (ENSG00000166426), FABP4 (ENSG00000170323), FABP12 (ENSG00000197416), FABP9 (ENSG00000205186)

Protein

Protein identifiers

Gastrotropin — P51161 (reviewed: P51161)

Alternative names: Fatty acid-binding protein 6, Ileal lipid-binding protein, Intestinal 15 kDa protein, Intestinal bile acid-binding protein

All UniProt accessions (2): P51161, H0YB64

UniProt curated annotations — full annotation on UniProt →

Function. Binds to bile acids and is involved in enterohepatic bile acid metabolism. Required for efficient apical to basolateral transport of conjugated bile acids in ileal enterocytes. In vitro binds to bile acids in the order: deoxycholic acid > cholic acid > chenodeoxycholic acid and respective BA conjugation modifies affinities in the order taurine-conjugated > glycine-conjugated > unconjugated bile acids. Stimulates gastric acid and pepsinogen secretion. Essential for the survival of colon cancer cells to bile acid-induced apoptosis.

Subcellular location. Cytoplasm. Membrane Cytoplasm.

Tissue specificity. Isoform 1 is expressed in the jejunum, ileum, cecum and ascending colon intestine. Isoform 2 is xpressed in the gallbladder, duodenum, jejunum, ileum, cecum, ascending, transverse and descending colon, sigmoid colon and rectum. Isoform 2 is expressed in colorectal adenocarcinomas and their adjacent normal mucosa (at protein level).

Domain organisation. Forms a beta-barrel structure that accommodates the hydrophobic ligand in its interior. Can bind at least two ligands per molecule, however, the stoichiometry is debated.

Induction. Isoform 1 is up-regulated by chenodeoxycholic acid (CDCA) via the FXR transcription pathway. Isoform 2 is up-regulated by NF-kappa-B and in all stages of colorectal adenocarcinoma. Isoform 1 is not up-regulated in all stages of colorectal adenocarcinoma.

Similarity. Belongs to the calycin superfamily. Fatty-acid binding protein (FABP) family.

Isoforms (2)

UniProt IDNamesCanonical?
P51161-11yes
P51161-22, IBABP-L

RefSeq proteins (3): NP_001035532, NP_001124430, NP_001436* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR000463Fatty_acid-bdDomain
IPR012674CalycinHomologous_superfamily
IPR031259ILBPFamily

Pfam: PF14651

UniProt features (22 total): strand 12, sequence variant 3, helix 2, initiator methionine 1, chain 1, turn 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

6 structures.

PDBMethodResolution (Å)
5L8IX-RAY DIFFRACTION1.88
5L8NX-RAY DIFFRACTION2.12
5L8OX-RAY DIFFRACTION2.39
1O1USOLUTION NMR
1O1VSOLUTION NMR
2MM3SOLUTION NMR

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-P51161-F190.410.64

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

IDPathway
R-HSA-159418Recycling of bile acids and salts
R-HSA-163560Triglyceride catabolism
R-HSA-9623433NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis

MSigDB gene sets: 90 (showing top): REACTOME_TRIGLYCERIDE_CATABOLISM, RNGTGGGC_UNKNOWN, FXR_IR1_Q6, GOBP_ORGANIC_ACID_TRANSPORT, YOKOE_CANCER_TESTIS_ANTIGENS, KEGG_PPAR_SIGNALING_PATHWAY, GOBP_ORGANIC_ANION_TRANSPORT, NAKAMURA_LUNG_CANCER_DIFFERENTIATION_MARKERS, GOBP_LIPID_METABOLIC_PROCESS, RICKMAN_HEAD_AND_NECK_CANCER_A, GOBP_MONOCARBOXYLIC_ACID_TRANSPORT, NAKAMURA_BRONCHIAL_AND_BRONCHIOLAR_EPITHELIA, GOBP_LIPID_LOCALIZATION, GOBP_FATTY_ACID_TRANSPORT, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN

GO Biological Process (4): lipid metabolic process (GO:0006629), negative regulation of cell population proliferation (GO:0008285), fatty acid transport (GO:0015908), lipid transport (GO:0006869)

GO Molecular Function (2): fatty acid binding (GO:0005504), lipid binding (GO:0008289)

GO Cellular Component (4): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

CategoryPathways
Bile acid and bile salt metabolism1
Triglyceride metabolism1
NR1H2 and NR1H3-mediated signaling1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular anatomical structure3
primary metabolic process1
cell population proliferation1
regulation of cell population proliferation1
negative regulation of cellular process1
lipid transport1
monocarboxylic acid transport1
transport1
lipid localization1
lipid binding1
monocarboxylic acid binding1
binding1
intracellular membrane-bounded organelle1
intracellular anatomical structure1
cytoplasm1

Protein interactions and networks

STRING

870 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
FABP6SLC10A2Q12908916
FABP6ABCB11O95342886
FABP6NR1H4Q96RI1866
FABP6SLC10A1Q14973858
FABP6NR0B2Q15466852
FABP6CYP7A1P22680833
FABP6GOT2P00505810
FABP6SLC51AQ86UW1810
FABP6FABP2P12104809
FABP6SLC51BQ86UW2773
FABP6NR5A2O00482733
FABP6ABCC4O15439730
FABP6NR1I2O75469697
FABP6ATP6V0CP27449674
FABP6XPR1Q9UBH6669

IntAct

3 interactions, top by confidence:

ABTypeScore
C7FABP6psi-mi:“MI:0915”(physical association)0.400
OSBPL8FABP6psi-mi:“MI:0914”(association)0.350

BioGRID (4): FABP6 (Affinity Capture-MS), FABP6 (Affinity Capture-MS), FABP6 (PCA), FABP6 (PCA)

ESM2 similar proteins: A0A182IRF8, A0A1S4K3K8, A0A6I8TMQ9, A2IA90, A9LKE4, A9LKE6, A9LKF0, A9LKF6, C0HM19, G5EGI7, J7MAN2, J7MFT5, O55057, O55159, P0CU39, P0CU40, P0CU41, P0CU42, P0DM59, P10289, P14948, P16422, P50119, P51161, P54962, Q00630, Q04669, Q09294, Q18268, Q18594, Q1WER1, Q20222, Q26239, Q26241, Q27042, Q3T0Z2, Q5ECE3, Q5ENZ6, Q5ENZ7, Q5EP01

Diamond homologs: A0A0K0MJ13, A0A0K0MJN3, A6NFH5, A6YLM6, A8MUU1, B7SUM8, C4N147, O01812, O01814, O02323, O02324, O02772, O08716, O13008, O15540, O42386, O45035, O76821, O97788, P02689, P02690, P02691, P02693, P02694, P02696, P04117, P05413, P06768, P07483, P09455, P0C241, P0C6G6, P0DM59, P10790, P11404, P12104, P15090, P22935, P24526, P29373

SIGNOR signaling

1 interactions.

AEffectBMechanism
FABP6“up-regulates quantity”“Fatty acid”relocalization

Disease & clinical

Clinical variants and AI predictions

ClinVar

32 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance26
Likely benign0
Benign2

Top pathogenic / likely-pathogenic (0)

SpliceAI

329 predictions. Top by Δscore:

VariantEffectΔscore
5:160229622:TTGGT:Tdonor_loss1.0000
5:160229624:GGTG:Gdonor_loss1.0000
5:160229625:G:Cdonor_loss1.0000
5:160229625:G:GGdonor_gain1.0000
5:160229626:T:Adonor_loss1.0000
5:160229629:G:GGdonor_gain1.0000
5:160232089:C:Aacceptor_gain1.0000
5:160232090:G:Aacceptor_gain1.0000
5:160232095:CAG:Cacceptor_loss1.0000
5:160232096:A:AGacceptor_gain1.0000
5:160232096:AG:Aacceptor_gain1.0000
5:160232096:AGG:Aacceptor_gain1.0000
5:160232097:G:GCacceptor_loss1.0000
5:160232097:G:GGacceptor_gain1.0000
5:160232097:GG:Gacceptor_gain1.0000
5:160232097:GGG:Gacceptor_gain1.0000
5:160232097:GGGA:Gacceptor_gain1.0000
5:160232236:A:Tdonor_gain1.0000
5:160232271:AAGG:Adonor_loss1.0000
5:160232274:G:GAdonor_loss1.0000
5:160232274:G:GGdonor_gain1.0000
5:160232275:T:Gdonor_loss1.0000
5:160234815:TCCA:Tacceptor_loss1.0000
5:160234817:CAG:Cacceptor_loss1.0000
5:160234818:A:AGacceptor_gain1.0000
5:160234818:A:Cacceptor_loss1.0000
5:160234818:AG:Aacceptor_gain1.0000
5:160234819:G:Cacceptor_loss1.0000
5:160234819:G:GGacceptor_gain1.0000
5:160234819:GG:Gacceptor_gain1.0000

AlphaMissense

860 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
5:160238637:G:CR122P0.988
5:160232221:T:CF64S0.983
5:160229576:T:CF7L0.982
5:160229578:C:AF7L0.982
5:160229578:C:GF7L0.982
5:160232172:T:CF48L0.980
5:160232173:T:CF48S0.980
5:160232174:C:AF48L0.980
5:160232174:C:GF48L0.980
5:160232178:T:AW50R0.980
5:160232178:T:CW50R0.980
5:160234880:T:CS102P0.978
5:160229609:T:CF18L0.977
5:160229611:C:AF18L0.977
5:160229611:C:GF18L0.977
5:160234902:T:CL109P0.973
5:160232220:T:CF64L0.972
5:160232222:C:AF64L0.972
5:160232222:C:GF64L0.972
5:160238642:A:CS124R0.970
5:160238644:C:AS124R0.970
5:160238644:C:GS124R0.970
5:160238609:T:CS113P0.964
5:160232152:T:AV41E0.963
5:160229564:T:CF3L0.957
5:160229566:C:AF3L0.957
5:160229566:C:GF3L0.957
5:160229610:T:CF18S0.956
5:160232181:T:CS51P0.956
5:160234827:T:AV84E0.952

dbSNP variants (sampled 300 via entrez): RS1000012494 (5:160225102 T>G), RS1000041609 (5:160192645 C>T), RS1000067953 (5:160186199 A>ACTT), RS1000129996 (5:160230570 C>G,T), RS1000153812 (5:160206855 G>A,C), RS1000175296 (5:160208720 G>A), RS1000191096 (5:160205067 A>C), RS1000206747 (5:160207210 G>C,T), RS1000270172 (5:160208439 TAA>T,TA,TAAA), RS1000321237 (5:160208085 T>C), RS1000348515 (5:160208559 C>T), RS1000372848 (5:160236107 C>G), RS1000402439 (5:160208181 G>A), RS1000450738 (5:160202973 C>T), RS1000471410 (5:160224918 C>A,T)

Disease associations

OMIM: gene MIM:600422 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

StudyTraitp-value
GCST005991_85Platelet count3.000000e-17
GCST006101_2Cardiometabolic and hematological traits2.000000e-31
GCST006979_479Heel bone mineral density8.000000e-11
GCST90002395_470Mean platelet volume4.000000e-17
GCST90002401_29Platelet distribution width2.000000e-21
GCST90002401_30Platelet distribution width8.000000e-09
GCST90002402_715Platelet count3.000000e-17

EFO canonical traits (3, from GWAS)

EFO IDTrait name
EFO:0004309platelet count
EFO:0009270heel bone mineral density
EFO:0007984platelet component distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523235 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 35,360 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

MoleculeNamePhasePatents
CHEMBL95TACRINE435,360

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Fatty acid-binding proteins

ChEMBL bioactivities

1 potent at pChembl≥5 of 13 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChemblTypeValueUnitMolecule
5.55Kd2800nMCHEMBL3793369

PubChem BioAssay actives

1 with measured affinity, of 45 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

CompoundAssayTypeValueUnit
5,6-dimethyl-1H-benzimidazol-2-amine1632113: Binding affinity to recombinant human N-terminal His6 and Avi-tagged FABP6 expressed in Escherichia coli NEB cells by 2 site binding model based surface plasmon resonance methodkd2.8000uM

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
Chenodeoxycholic Acidaffects binding, increases activity, increases expression, decreases reaction3
Valproic Acidaffects cotreatment, decreases expression, affects methylation3
sodium arseniteincreases expression2
perfluorooctanoic aciddecreases expression, increases expression2
Benzo(a)pyreneaffects methylation, increases methylation2
p-Chloromercuribenzoic Acidincreases expression, affects cotreatment2
propionaldehydeincreases expression1
deoxynivalenoldecreases expression1
beta-lapachonedecreases expression1
tris(1,3-dichloro-2-propyl)phosphatedecreases expression1
butyraldehydeincreases expression1
benzo(e)pyreneincreases methylation1
S-(1,2-dichlorovinyl)cysteineaffects cotreatment, increases expression1
pentanalincreases expression1
perfluorooctane sulfonic acidincreases expression1
entinostatdecreases expression1
GW 4064increases expression1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideaffects cotreatment, increases expression, decreases expression1
nutlin 3affects cotreatment, increases expression1
trans-10,cis-12-conjugated linoleic acidincreases expression1
dorsomorphinincreases expression, decreases expression, affects cotreatment1
Irinotecanincreases expression1
Resveratrolaffects cotreatment, decreases expression1
Vorinostatdecreases expression1
Acetaminophendecreases expression1
Aldehydesincreases expression1
Arsenicaffects methylation1
Ascorbic Acidaffects cotreatment, decreases expression1
Dactinomycinaffects cotreatment, increases expression1
Deoxycholic Acidincreases expression1

ChEMBL screening assays

9 unique, capped per target: 9 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL4432266BindingBinding affinity to recombinant human N-terminal His6 and Avi-tagged FABP6 expressed in Escherichia coli NEB cells by surface plasmon resonance methodIdentification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6). — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 80

This page pulls from 80 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgtopdb_interactiongwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot